

# INTERPLAY OF BRAIN-DERIVED NEUROTROPHIC FACTOR AND CYTOKINES IN SCHIZOPHRENIA

Slavica Minić Janićijević<sup>1</sup>, Slavica Djukić Dejanović<sup>2</sup>, Milica Borovčanin<sup>2,3</sup>

<sup>1</sup>University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia

<sup>2</sup>University of Kragujevac, Faculty of Medical Sciences, Department of Psychiatry, Kragujevac, Serbia

<sup>3</sup>University of Kragujevac, Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia

## MEĐUSOBNA DEJSTVA MOŽDANOG NEUROTROFIČNOG FAKTORA I CITOKINA U SHIZOFRENIJI

Slavica Minić Janićijević<sup>1</sup>, Slavica Đukić Dejanović<sup>2</sup>, Milica Borovčanin<sup>2,3</sup>

<sup>1</sup>Univerzitet u Kragujevcu, Fakultet medicinskih nauka, Kragujevac, Srbija

<sup>2</sup>Univerzitet u Kragujevcu, Fakultet medicinskih nauka, Katedra za psihijatriju, Kragujevac, Srbija

<sup>3</sup>Univerzitet u Kragujevcu, Fakultet medicinskih nauka, Centar za molekulske medicine i istraživanje matičnih ćelija, Kragujevac, Srbija

Name and full location of the department and institution where work was performed:

Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

Received / Priljen: 12. 06. 2016.

Accepted / Prihvaćen: 29. 11. 2016.

### ABSTRACT

*Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family and plays an important role in neuroplasticity, differentiation and survival of neurons, as well as their function. Neuroinflammation has been explored in the pathophysiology of many mental disorders, such as schizophrenia. Cytokines representing different types of immune responses have an impact on neurogenesis and BDNF expression. Cross-regulation of BDNF and cytokines is accomplished through several signalling pathways. Also, typical and atypical antipsychotic drugs variously modulate the expression of BDNF and serum levels of cytokines, which can possibly be used in evaluation of therapy effectiveness. Comorbidity of metabolic syndrome and atopic diseases has been considered in the context of BDNF and cytokines interplay in schizophrenia.*

**Keywords:** brain derived neurotrophic factor, cytokines, schizophrenia, metabolic syndrome, atopic diseases.

### SAŽETAK

*Moždani neurotrofični faktor (Brain Derived Neurotrophic Factor-BDNF) pripada porodici neurotrofina i ima važnu ulogu u neuroplastičnosti, diferencijaciji i funkciji neurona. Neuroinflamacija je izučavana u etiopatogenezi mnogih mentalnih poremećaja, pa i u shizofreniji. Citokini različitih tipova imunskih odgovora utiču na neurogenezu i ekspresiju BDNF-a. Unakrsna regulacija BDNF-a i citokina se ostvaruje posredstvom nekoliko signalnih puteva. Pokazano je da tipični i atipični antipsihotici mogu drugačije da utiču na ekspresiju BDNF-a i serumske nivoe citokina, što može biti korisno u proceni efikasnosti terapije. Komorbiditet metaboličkog sindroma i atopijskih bolesti je razmatran i u kontekstu uzajamnog dejstva BDNF-a i citokina u shizofreniji.*

**Ključne reči:** moždani neurotrofni faktor, citokini, shizofrenija, metabolički sindrom, atopijske bolesti.

### ABBREVIATIONS

<b>AD-</b> Atopic dermatitis	<b>MetS-</b> Metabolic Syndrome
<b>BDNF-</b> Brain Derived Neurotrophic Factor	<b>p75 NTR-</b> p75 NeuroTrophin Receptor
<b>CREB-</b> Cyclic adenosine monophosphate Response Element- Binding	<b>PANSS-</b> Positive and Negative Syndrome Scale
<b>IFN-<math>\gamma</math>-</b> Interferon-gamma	<b>ST2- IL-1 receptor-</b> related protein
<b>IL-</b> Interleukin	<b>TNF-<math>\alpha</math>-</b> Tumor Necrosis Factor-alpha
	<b>TrkB-</b> Tropomyosin receptor kinase B

### INTRODUCTION

The Brain Derived Neurotrophic Factor (BDNF) is a member of the nerve growth factor family (1). It plays an important role in neuronal survival and growth, modulates neurotransmission and participates as a crucial mediator in all aspects of neuroplasticity (2), such as neurogenesis (3), synaptogenesis (4) and vasculogenesis (5). BDNF participates in learning and memory organization, food intake and motor behaviour (6).

It was shown that BDNF is widely distributed in various regions of the brain, such as the olfactory bulb, cortex, hippocampus, basal forebrain, mesencephalon, hypothalamus, brainstem and spinal cord (2, 7, 8). BDNF promotes the survival of dopaminergic neurons of the substantia nigra (9), cerebellar granule neurons (10), motor neurons (11) and retinal ganglion cells (12).



UDK: 616.895.8

Ser J Exp Clin Res 2020; 21 (4): 283-289

DOI: 10.1515/sjocr-2017-0031

**Corresponding author:**

Slavica Minić Janićijević, Doctor of Medicine, PhD Student at the Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

Tel: +381 637695226;

E-mail address: redslavica@yahoo.com




Figure 1. Brain-derived neurotrophic factor (BDNF) - cytokines interactions in schizophrenia and comorbid somatic states

In animal models application of IL-1 $\beta$  decreases BDNF levels in the nerve tissue and lead to degeneration. BDNF- IL-6 communication could be bidirectional. IL-17 up-regulates BDNF microglia production. (A) In schizophrenia was established significant positive association between BDNF and IL-2 and IL-8 levels. (B) TNF- $\alpha$  and IL-6 increase BDNF production in peripheral blood monocytes, that also underlies neuronal hyperreactivity in asthma. BDNF induces eosinophil increase in patients with atopic dermatitis and that could be a side effect of clozapine, an antipsychotic with BDNF- elevating properties. (C) In metabolic syndrome increase of inflammatory cytokines IL-6, TNF- $\alpha$  and IL-1 $\beta$  could reduce BDNF expression. (D)

Microglia and activated macrophages produce BDNF in the brain (13, 14). Human monocytes, but not lymphocytes, are the major cellular source of BDNF in peripheral tissues (15). Furthermore, it is found in the nonneuronal tissue such as lungs, heart, spleen, gastrointestinal tract and liver (16-18) and it is expressed in fibroblasts, vascular smooth muscle cells, and thymic stroma (5, 19, 20). BDNF is involved in activation of endothelial cells (21) and has an influence on the hematopoietic stem cells and thus supports haematopoiesis (22).

The BDNF gene is located on the short (p) arm of chromosome 11 at position 13 (23). As a basic dimeric protein (1), BDNF has a complex genomic structure, with sophisticated organization in terms of transcriptional, translational and post-translational regulatory mechanisms (24). Pro-BDNF is produced in endoplasmatic reticulum, transported to the Golgi apparatus and converted into mature BDNF (25). The receptor for BDNF is Tropomyosin receptor kinase B (TrkB), which exists in two isoforms: the full length receptor glycoprotein (gp145TrkB) with high affinity and truncated form gp-95TrkB lacking tyrosine kinase domain; and the Low affinity Nerve Growth Factor Receptor, also known as p75 NeuroTrophin Receptor (p75 NTR) (2).

BDNF levels in the cerebrospinal fluid in healthy controls were measured in the range of 98.1 $\pm$ 83.99 (26). In healthy volunteers, mean plasma BDNF level was found to be ~92.5 pg/ml (8.0–927.0 pg/ml) (2). In schizophrenia, drug-naïve patients had a significant correlation between BDNF protein levels in plasma and cerebrospinal fluid (27).

The BDNF can freely pass through blood-brain barrier and all of this suggests that BDNF blood levels can substantially reflect its levels in the central nervous system (28).

### The role of BDNF and cytokines in central nervous system and peripheral tissues

Neuroinflammation has an important role in the pathophysiology of mental disorders and pro-inflammatory cytokines and BDNF may have a detrimental effect on neurogenesis, reviewed by Calabrese et al. (29). The impact of the pro-inflammatory cytokines on neurogenesis depends on their concentration, activation of specific cells and neurogenic factors (30). Different stimuli regulate BDNF production in neurons, such as Cyclic adenosine monophosphate Response Element-Binding protein (CREB) - dependent depolarization (31) and cytokines (32).

In study of Lapchak et al. (1993) the mRNA levels of BDNF were significantly decreased in the rat's hippocampus after 4 hours of intraperitoneal injection of interleukin (IL)-1 $\beta$  (33). Application of IL-1 $\beta$  reduces the expression of BDNF through suppression of apoptosis repressor with caspase recruiting domain, CREB and insulin receptor substrate 1 response or by increasing the phosphorylation of p38 mitogen-activated protein kinase (34). Similarly to IL-1 $\beta$  pathways insulin resistance in peripheral tissues (35), the "neurotrophic factor resistance" may be associated with elevation of proinflammatory cytokines, predisposing neurons to dysfunction and increased risk for degeneration (36), as shown in Figure 1A.

Some findings suggest that cytokines could not only inhibit, but also stimulate BDNF expression in neurons and thus improve neuronal survival. Intrathecal infusion of IL-6 in rats increases the concentration of BDNF mRNA in rat lumbal dorsal root ganglia (32) (Figure 1A). Tumor Necrosis Factor-alpha (TNF- $\alpha$ ) and IL-6 increase BDNF production in human peripheral blood monocytes (Figure 1C), but IL-1 $\beta$ , Interferon-gamma (IFN- $\gamma$ ), IL-2, IL-4, IL-5, IL-13 and IL-15 did not have any effect on BDNF monocyte production (15). Treatment with IL-17 up-regulated the microglia production of neurotrophic factors (37) (Figure 1A).

The BDNF-cytokine communication seems to be rather bidirectional (presented in Figure 1A). In study of Lin et al. (2016) has been shown that application of BDNF in human Schwann cells increased the secretion of IL-6 through the Janus kinase- signal transducer and activator of transcription pathway activation (38), crucial for the development and function of the immune system (39). Also, wild type mice (BDNF<sup>+/+</sup>) display higher IL-10 secretion in response to low-level stress compared to BDNF-deficient mice (40).

### The role of BDNF and cytokines in schizophrenia

The BDNF ability to augment neuroplasticity implies that low BDNF levels may have a role in cognitive declining



observed in Alzheimer's disease, dementia (41, 42), schizophrenia (43), depression (44), and bipolar disorder (45). The influence of BDNF on dopaminergic neurons may be relevant to the pathogenesis of schizophrenia and reflect the severity or the neuronal degeneration in schizophrenia (9). BDNF increases neuronal dopamine content: modulates dopamine release relevant for neuronal plasticity in the ventral tegmental area (46) and also decreases dopamine in mesolimbic dopaminergic system (47). Reduction in BDNF expression was observed in the prefrontal cortex, striatum and hippocampus in animal models and patients with schizophrenia (48-50).

The microglia appeared to be activated in schizophrenia and have provided the main source of pro-inflammatory cytokines (51) and BDNF secretion (13, 14). The etiopathogenesis of schizophrenia is obviously related to the inflammatory responses mediated by microglia (52, 53).

Our previous results in early phases of schizophrenia suggested that type-1 and type-17 immune responses are decreased (54), type-2 response is increased and could be corrected with antipsychotics (55, 56), and higher serum levels of Transforming growth factor beta and IL-23 were measured regardless of applied therapy (57, 58).

BDNF regulation has been shown in many different types of inflammation and seems that it is not type-1 or type-2 restricted: serum levels of BDNF in schizophrenia are not in correlation with serum levels of IL-1 $\beta$ , IL-6, IL-8, IL-10, IL-12 and TNF- $\alpha$  (59), but Zhang (2016) showed a significant positive association between BDNF and IL-2 and IL-8 levels (60) (see in Figure 1B). These data are in correspondence with lower level of IL-2 in patients with early onset disease and predisposition for negative form of schizophrenia (61). Also, higher levels of IL-8 in second trimester have been linked to a higher risk for schizophrenia development (62).

The correlation between serum BDNF levels and Positive and Negative Syndrome Scale (PANSS) scores was not established in patients with schizophrenia (59, 63), but recently low BDNF levels were associated with impairment on the PANSS cognitive factor (60) and also with low cognitive scores on the Repeatable battery for the assessment of neuropsychological Status (64).

A recent meta analysis of Green et al. (2011) point out that blood levels of BDNF are reduced in both medicated and drug-naive patients with schizophrenia (65). Some studies have found a different regulation of BDNF mRNA expression in the rat hippocampus and neocortex after typical and atypical antipsychotic administration (66), where the typical antipsychotic drug haloperidol down-regulated BDNF mRNA expression and atypical antipsychotics olanzapine and clozapine up-regulated BDNF mRNA expression (67) (Figure 1C). Serum BDNF levels were higher in patients with chronic schizophrenia on clozapine or typical antipsychotics, than risperidone (68). Others showed significant decrease of IL-1 $\beta$  plasma levels and increase of TNF- $\alpha$  and BDNF after risperidone treatment (49). Some longitudinal studies have reported that lower serum BDNF levels did not increase after several weeks of antipsychotic treatment (63, 68).

Schizophrenia is associated with metabolic syndrome, expressed by type-2 diabetes and insulin insensitivity (69). This could be discussed as a consequence of unhealthy lifestyle or as a genetic predisposition that is potentiated with antipsychotic therapy (51). In schizophrenia, as in obesity, there is an imbalance between adiponectin and the pro-inflammatory cytokines TNF- $\alpha$  and IL-6 (70). Also, BDNF deficiency has been reported in increased food intake, hyperphagia and obesity (71). Obesity itself does not affect the value of BDNF in the serum in adults (72), but BDNF levels in plasma were decreased in patients with Metabolic Syndrome (MetS) compared with control subjects (73) (Figure 1D). For the first time, Zhang et al. (2013) tested the relationship between the BDNF Val66Met polymorphism and MetS in patients with schizophrenia under long-term clozapine treatment. BDNF serum levels appeared to be associated with clozapine-induced MetS, and that effect is only evident in male patients (71).

### **BDNF and cytokines in schizophrenia and atopic diseases**

Results of Pedersen et al. (2012) indicated comorbidity of schizophrenia and atopic diseases, both with predominance of type-2 immune response (74). In humans, as well as in mouse models of asthma, allergen challenge increases BDNF levels in bronchoalveolar lavage fluid (75). Such increase may be a result of enhanced BDNF secretion by resident airway cells, immune cells including B-lymphocytes, eosinophils, mast cells and macrophages (75). BDNF in the presence of cytokines TNF- $\alpha$  and IL-13 increases proliferation of human airway smooth muscle in asthma (75). In vitro, increase of BDNF in sputum, in response to IL-13, suggests that type-2 cytokines regulate BDNF levels and activity in asthma (76). After antipsychotic treatment significant decrease of IL-13 was observed, suggesting that the BDNF-IL-13 interaction could be more thoroughly explored in schizophrenia (77). Also, IL-33, recently discovered IL-1 family member, plays a role in induction of airway contraction by stimulating expansion of IL-13-producing innate lymphoid cells (78). IL-33/ST2 signalling pathway regulates T cells, differentiation and activation of dendritic cells, activation of macrophages and mast cells and production of type 2 cytokine producing innate lymphoid cells, showed to be important in type-2 immune response in development of spontaneous obesity (79) and atopic disorders, particularly asthma (80).

As it is seen in asthma, BDNF levels are increased in serum, plasma and eosinophils in patients with atopic dermatitis (AD) (81). Patients with AD had higher eosinophilic expression of p75 NTR and TrkB in comparison with nonatopic control subjects (81). Furthermore, it has been shown that BDNF induces chemotaxis and inhibits apoptosis of eosinophils in patients with AD, indicating its role in proinflammatory actions (81). Increase in eosinophilic



count was also observed as a side effect of clozapine, an antipsychotic with BDNF-elevating properties (82). A common genetic variant of BDNF gene was associated with increased risk for developing allergic rhinitis (83). Mechanism of IL-6 and TNF- $\alpha$  induced neuronal hyperactivity in the allergic asthmatic patients is mediated by BDNF-secreting monocytes (15) (shown in Figure 1C).

## CONCLUSION

Intriguing concept of neuroplasticity has introduced new approaches in basic and clinical research. The role of BDNF, as a member of nerve growth factor family, has been explored not exclusively in the central nervous system, but also in other peripheral tissues. Low BDNF levels or “neurotrophic factor resistance” associated with elevation of pro-inflammatory cytokines could have an impact in schizophrenia cognitive declining. The BDNF-cytokines interactions are not only restricted to type-1 or type-2 immune response. The role of IL-33/ST2 signalling pathway has been observed in MetS and atopic disorders, which are closely related to schizophrenia. This could be a rationale for further research of IL-33 and BDNF interplay in schizophrenia, aiming to improve cognitive functioning and prevent metabolic dysfunction in patients with schizophrenia.

### Role of the funding source

This work was supported by grants from the Ministry of Science and Technological Development of Republic of Serbia (projects 175103 and 175069) and from the Faculty of Medical Sciences, University of Kragujevac (project JP 12-09 and JP 05-15).

### Contributors

All authors contributed to and have approved the final manuscript.

### Conflict of interest

The authors report no conflicts relevant to this paper.

### Acknowledgement

None.

## REFERENCES

- Mizuno K, Carnahan J, Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. *Dev Biol.* 1994; 165(1): 243–256.
- Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. *Arch Med Sci.* 2015; 11(6): 1164–78.
- Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. *Mol Cell Neurosci.* 1998; 11: 234–45.
- Carrasco MA, Castro P, Sepulveda FJ, Tapia JC, Gatica K, Davis MI, Aguayo LG. Regulation of glycinergic and GABAergic synaptogenesis by brain-derived neurotrophic factor in developing spinal neurons. *Neuroscience.* 2007; 145(2): 484–494.
- Donovan MJ, Miranda RC, Kraemer R, et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. *Am J Pathol.* 1995; 147: 309–24.
- Levada OA, Cherednichenko NV. [Brain-derived neurotrophic factor (BDNF): neurobiology and marker value in neuropsychiatry]. *Lik Sprava.* 2015; (3-4): 15–25.
- Hashimoto R, Ohi K, Yamamori H, Yasuda Y, Fujimoto M, Umeda-Yano S, Watanabe Y, Fukunaga M, Takeda M. Imaging Genetics and Psychiatric Disorders. *Curr Mol Med.* 2015; 15(2): 168–175.
- Kim A, Fagan AM, Goate AM, Benzinger TLS, Morris JC, Head D. Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory. *Cogn Affect Behav Neurosci.* 2015; 15: 625–643.
- Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature.* 1991; 350 (6315): 230–232.
- Segal RA, Takahashi H, McKay RD. Changes in neurotrophin responsiveness during the development of cerebellar granule neurons. *Neuron.* 1992; 9(6): 1041–1052.
- Oppenheim RW, Yin QW, Prevette D, Yan Q. Brain-derived neurotrophic factor rescues developing avian motoneurons from cell death. *Nature.* 1992; 360(6406): 755–757.
- Johnson JE, Barde YA, Schwab M, Thoenen H. Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. *J Neurosci.* 1986; 6(10): 3031–3038.
- Elkabes S, DiCicco-Bloom E.M, Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. *J Neurosci.* 1996; 16, 2508e2521.
- Batchelor PE, Liberatore GT, Wong JY, Porritt MJ, Frerichs F, Donnan GA, Howells DW. Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor. *The Journal of Neuroscience,* March 1, 1999; 19(5): 1708–1716.
- Schulte-Herbrüggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A. Tumor necrosis factor- $\alpha$  and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. *Neuroimmunol* 2005; 160(1-2):204–9.
- Rosenthal A, Goeddel DV, Nguyen T, Martin E, Burton LE, Shih A, Laramée GR, Wurm F, Mason A, Nikolics K, Winslow JW: Primary structure and biological activity of human brain-derived neurotrophic factor. *Endocrinology* 1991; 129: 1289–1294.



17. Yamamoto M, Sobue G, Yamamoto K, Terao S, Mitsuma T: Expression of mRNAs for neurotrophic factors (NGF, BDNF, NT-3, and GDNF) and their receptors (p75NGFR, trkA, trkB, and trkC) in the adult human peripheral nervous system and nonneural tissues. *Neurochem Res* 1996; 21: 929-938.
18. Katoh-Semba R, Takeuchi IK, Semba R, Kato K: Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. *J Neurochem* 1997; 69: 34-42.
19. Scarisbrick IA, Jones EG, Isackson PJ: Coexpression of mRNAs for NGF, BDNF, and NT-3 in the cardiovascular system of the pre- and postnatal rat. *J Neurosci* 1993; 13: 875-893.
20. Maroder M, Bellavia D, Meco D, Napolitano M, Stigliano A, Alesse E, Vacca A, Giannini G, Frati L, Gulino A, Screpanti I: Expression of trkB neurotrophin receptor during T cell development: role of brain derived neurotrophic factor in immature thymocyte survival. *J Immunol* 1996; 157: 2864-2872.
21. Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, Kawaguchi H, Kurihara H. Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin  $\alpha$ v $\beta$ 3-FAK cascade. *J Cell Physiol*. 2012; 227(5): 2123-9.
22. Dormady SP, Bashayan O, Dougherty R, Zhang XM, Basch RS. Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment. *J Hematother Stem Cell Res*. 2001; 10(1): 125-40.
23. Dwivedi Y. Involvement of Brain-Derived Neurotrophic Factor in Late-Life Depression. *Am J Geriatr Psychiatry*. 2013; 21(5): 433-449.
24. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. *J Neurosci Res*. 2007; 85(3): 525-35.
25. Akyol ES, Albayrak Y, Beyazyüz M, Aksoy N, Kuloglu M, Hashimoto K. Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome. *Neuropsychiatr Dis Treat*. 2015; 11: 865-72.
26. Diniz B.S, Teixeira A.L, Machado-Vieira R, Talib L.L, Radanovic M, Gattaz W.F, Forlenza O.V. Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. *Journals of Gerontology, Series B: Psychological Sciences and Social Sciences*, 2014; 69(6): 845-851.
27. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. *Int J Neuropsychopharmacol*. 2010; 13(4): 535-9.
28. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. *Neuropharmacology*. 1998; 37(12): 1553-61.
29. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. *Front Cell Neurosci*. 2014; 8: 430.
30. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. *Psychoneuroendocrinology*. 2012; 37(9): 1397-1416.
31. Zha XM, Bishop JE, Hansen MR, Victoria L, Abbas PJ, Mouradian MM, Green SH. BDNF synthesis in spiral ganglion neurons is constitutive and CREB-dependent. *Hear Res*. 2001; 156 (1-2): 53-68.
32. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM. Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. *Eur J Neurosci* 2000; 12(6): 1891-9.
33. Lapchak PA, Araujo DM, Hefti F. Systemic interleukin-1 betadecreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. *Neuroscience*. 1993; 53(2): 297-301.
34. Tong L, Prieto GA, Kramár EA, Smith ED, Cribbs DH, Lynch G, Cotman CW. Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1 $\beta$  via p38 mitogen-activated protein kinase. *J Neurosci* 2012; 32: 17714-24.
35. Böni-Schnetzler M, Donath MY. Increased IL-1 $\beta$  activation, the culprit not only for defective insulin secretion but also for insulin resistance? *Cell Res*. 2011; 21(7): 995-7.
36. Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. *Neurobiol Aging* 2008; 29(9): 1380-93.
37. Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, Suzumura A. Production and functions of IL-17 in microglia. *J Neuroimmunol*. 2008; 194(1-2): 54-61.
38. Lin G, Zhang H, Sun F, Lu Z, Reed-Maldonado A, Lee YC, Wang G, Banie L, Lue TF. Brain-derived neurotrophic factor promotes nerve regeneration by activating the JAK/STAT pathway in Schwann cells. *Transl Androl Urol*. 2016; 5(2): 167-75.
39. Liongue C, O'Sullivan LA, Trengove MC, Ward AC. Evolution of JAK-STAT pathway components: mechanisms and role in immune system development. *PLoS One*. 2012; 7(3): e32777.
40. Dugan AM, Parrott JM, Redus L, Hensler JG, O'Connor JC. Low-Level Stress Induces Production of Neuroprotective Factors in Wild-Type but Not BDNF $\pm$  Mice: Interleukin-10 and Kynurenic Acid. *Int J Neuropsychopharmacol* 2015; 19(3): pyv089.
41. Phillips HS, Hains JM, Armanini M, Laramée GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. *Neuron*. 1991; 7(5): 695-702.
42. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. *Nat Rev Neurol*. 2009; 5(6): 311-22.
43. Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Nakamura J. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical



- antipsychotic monotherapy. *World J Biol Psychiatry*. 2016; 13: 1-30.
44. Castrén E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. *Neurobiol Dis*. 2016; pii: S0969-9961(16)30169-3.
  45. Mansur RB, Santos CM, Rizzo LB, Asevedo E, Cunha GR, Noto MN, Pedrini M, Zeni-Graiff M, Cordeiro Q, Vinberg M, Kapczinski F, McIntyre RS, Brietzke E. Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. *Bipolar Disord*. 2016; 18(4): 373-8.
  46. Zsuga J, Tajti G, Papp C, Juhasz B, Gesztelyi R. FNDC5/irisin, a molecular target for boosting reward-related learning and motivation. *Med Hypotheses*. 2016; 90: 23-8.
  47. Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. *Neuroscience*. 2003; 119(3): 767-75.
  48. Fumagalli F, Bedogni F, et al. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. *Eur J Neurosci*. 2004; 20(5): 1348-1354.
  49. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, Lee IH, Chen PS, Yeh TL, Huang SY, Yang YK, Lu RB, Hong JS. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. *Neuroimmune Pharmacol*. 2012; 7(3): 656-64.
  50. Strube W, Nitsche MA, Wobrock T, Bunse T, Rein B, Herrmann M, Schmitt A, Nieratschker V, Witt SH, Rietschel M, Falkai P, Hasan A. BDNF-Val66Met Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study. *International Journal of Neuropsychopharmacology*. 2015; 18(4): pyu040.
  51. Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? *J Psychopharmacol*. 2012; 26(5 Suppl): 33-41.
  52. Monji A, Kato T.A, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, Yamauchi Y, Yamada S, Kanba S. Neuroinflammation in schizophrenia especially focused on the role of microglia. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 2013; 42: 115-121.
  53. Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, Kasai M, Utsumi H, Kanba S. Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? *Mini Rev Med Chem*. 2011; 11(7): 565-74.
  54. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. *J Psychiatr Res*. 2012; 46 (11): 1421-6.
  55. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. *Schizophr Res*. 2013; 147 (1): 103- 9.
  56. Stefanović V, Mihajlović G, Nenadović M, Dejanović SD, Borovcanin M, Trajković G. *Vojnosanit Pregl*. The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia. 2015; 72(12):1085-92.
  57. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML. Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia. *Psychoneuroendocrinology*. 2015; 56: 143- 7.
  58. Borovcanin M, Jovanovic I, Djukic Dejanovic S, Radosavljevic G, Arsenijevic N, Lukic ML. Possible role of TGF- $\beta$  pathways in schizophrenia. *Ser J Exp Clin Res* 2016; 17 (1): 3-8.
  59. Noto CS, Gadelha A, Belangero SI, Smith MAC, W. de Aguiar B, Panizzuti B, Mari JJ, Gama CS, Bressan RA, Brietzke E. Association of biomarkers and depressive symptoms in schizophrenia. *Neuroscience Letters*. 2011; 505(3): 282-5.
  60. Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Wu HE, Zunta-Soares GB, Huang XF, Kosten TR, Soares JC. Interaction of BDNF with cytokines in chronic schizophrenia. *Brain Behav Immun*. 2016; 51: 169-75.
  61. Mahendran R, Mahendran R, Chan YH. Interleukin-2 levels in chronic schizophrenia patients. *Ann Acad Med Singapore*. 2004; 33(3): 320-3.
  62. Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. *Am J Psychiatry*. 2004; 161(5): 889-95.
  63. Pirildar S, Gönül AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. *Prog Neuropsychopharmacol Biol Psychiatry*. 2004; 28(4): 709-13.
  64. Zhang XY, Liang J, Chen da C, Xiang, Hong Xiu M, Yang FD, Kosten A. T, Kosten R. T. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. *Psychopharmacology (Berl)*. 2012; 222: 277-84.
  65. Green M.J, Matheson S.L, Shepherd A, Weickert C.S, Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. *Mol. Psychiatry*. 2011; 16 (9): 960-972.
  66. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. *J Neurosci Res*. 2003; 71(1): 127-31.
  67. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, Chen da C, Kosten TR, Zhang XY. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009; 33(8): 1508-12.



68. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, Nakano Y, Shinkai K, Mitoma M, Ohta M, Shinkai T, Nakamura J. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxyprenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007; 31(5): 1072-7.
69. Holt RI, Bushe C and Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? *J Psychopharmacol*. 2005; 19 (Suppl.6): 56-65.
70. Jin H, Meyer JM, Mudaliar S and Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. *Schizophr Res*. 2008; 100: 70-85.
71. Zhang Y, Chen M, Wu Z, Chen J, Yu S, Fang Y, Zhang C. Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. *PLoS One*. 2013; 8(8): e72652.
72. Gajewska E, Sobieska M, Łojko D, Wieczorowska-Tobis K, Suwalska A. Obesity itself does not influence BDNF serum levels in adults. *Eur Rev Med Pharmacol Sci*. 2014; 18(21): 3246-50.
73. Chaldakov GN, Fiore M, Hristova MG, Aloe L. Metabotropic potential of neurotrophins: implication in obesity and related diseases? *Med Sci Monit*. 2003; 9(10): HY19-21.
74. Pedersen MS, Benros ME, Agerbo E, Børghlum AD, Mortensen PB. Schizophrenia in patients with atopic disorders with particular emphasis on asthma: a Danish population-based study. *Schizophr Res*. 2012; 138(1): 58-62.
75. Prakash YS, Martin RJ. Brain-derived neurotrophic factor in the airways. *Pharmacol Ther*. 2014; 143(1): 74-86.
76. Watanabe T, Fajt ML, Trudeau JB, Voraphani N, Hu H, Zhou X, Holguin F, Wenzel SE. Brain-Derived Neurotrophic Factor Expression in Asthma. Association with Severity and Type 2 Inflammatory Processes. *Am J Respir Cell Mol Biol*. 2015; 53(6): 844-52.
77. Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, Lee SJ, Lee C, Paik IH. Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines. *Int Immunopharmacol*. 2006; 6(4): 666-71.
78. Lu J, Kang J, Zhang C, Zhang X. The role of IL-33/ST2L signals in the immune cells. *Immunol Lett*. 2015; 164(1): 11-7.
79. Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, et al. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. *Nature*. 2015; 519 (7542): 242- 6.
80. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, Huang LC, Johnson D, Scanlon ST, McKenzie AN, Fallon PG, Ogg GS. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. *J Exp Med*. 2013; 210(13): 2939-50.
81. Raap U, Goltz C, Deneka N, Bruder M, Renz H, Kapp A and Wedi B. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. *J Allergy Clin Immunol*. 2005; 115(6):1268-75.
82. Zipris P, Melamed Y, Weizman A, Bleich A. Clozapine-Induced Eosinophilia and Switch to Quetiapine in a Patient with Chronic Schizophrenia with Suicidal Tendencies. *Isr J Psychiatry Relat Sci*. 2007; 44(1): 54-6.
83. Jin P, Andiappan AK, Quek JM, Lee B, Au B, Sio YY, Irwanto A, Schurmann C, Grabe HJ, Suri BK, Matta SA, Westra HJ, Franke L, Esko T, Sun L, Zhang X, Liu H, Zhang F, Larbi A, Xu X, Poidinger M, Liu J, Chew FT, Rotzschke O, Shi L, Wang de Y. A functional brain-derived neurotrophic factor (BDNF) gene variant increases the risk of moderate-to-severe allergic rhinitis. *J Allergy Clin Immunol*. 2015; 135(6): 1486-93.